 |
Video: What is a Stock Split?
|
 |
| Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the U.S. and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. According to our JBIO split history records, Jade Biosciences has had 1 split. | |
 |

Jade Biosciences (JBIO) has 1 split in our JBIO split history database. The split for JBIO took place on April 29, 2025. This was a 1 for 35 reverse split, meaning for each 35 shares of JBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 28.5714285714286 share position following the split.
When a company such as Jade Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the JBIO split history from start to finish, an original position size of 1000 shares would have turned into 28.5714285714286 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Jade Biosciences shares, starting with a $10,000 purchase of JBIO, presented on a split-history-adjusted basis factoring in the complete JBIO split history.

Growth of $10,000.00
With Dividends Reinvested
|
| Start date: |
07/01/2021 |
|
| End date: |
12/08/2025 |
|
| Start price/share: |
$679.35 |
|
| End price/share: |
$13.48 |
|
| Starting shares: |
14.72 |
|
| Ending shares: |
18.20 |
|
| Dividends reinvested/share: |
$2.40 |
|
| Total return: |
-97.55% |
|
| Average Annual Total Return: |
-56.60% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$245.50 |
|
| Years: |
4.44 |
|
| |
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/01/2021 |
|
| End date: |
12/08/2025 |
|
| Start price/share: |
$679.35 |
|
| End price/share: |
$13.48 |
|
| Dividends collected/share: |
$2.40 |
|
| Total return: |
-97.66% |
|
| Average Annual Total Return: |
-57.08% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$233.67 |
|
| Years: |
4.44 |
|
|
 |
| Date |
Ratio |
| 04/29/2025 | 1 for 35 |
|
 |